Multiple outlets report that the U.S. Department of Health and Human Services (HHS) is launching a coordinated effort under President Donald Trump aimed at strengthening American clinical research. Both sources frame the initiative as a response to global competition in medical research, noting that China has surpassed the United States in early-stage clinical trials. The reporting indicates that the effort is intended to improve the U.S. pipeline for bringing new treatments from early research into later development stages. The articles largely focus on the policy goal—building the “future of medicine” in the United States—and the international benchmark of trial activity where China leads in early-stage trials. Neither source, in the provided excerpts, specifies detailed program elements, funding levels, timelines, or specific regulatory or operational changes. Overall, the coverage presents the HHS effort as a coordinated government push to reinforce U.S. capacity and competitiveness in clinical research in light of changing global performance.